PHARM

Pharming Group NV (PHARM)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:PHARM
DataOraFonteTitoloSimboloCompagnia
24/04/202408:00GlobeNewswire Inc.Pharming Group to report first quarter 2024 financial results on May 8EU:PHARMPharming Group NV
24/04/202407:00GlobeNewswire Inc.Pharming to be honored as Industry Innovator at National Organization for Rare Disorders (NORD®) 2024 Rare Impact AwardsEU:PHARMPharming Group NV
19/04/202418:43GlobeNewswire Inc.Pharming Group announces the repurchase of outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
18/04/202415:04GlobeNewswire Inc.Pharming Group announces the placement of €100 million convertible bonds due 2029EU:PHARMPharming Group NV
18/04/202408:00GlobeNewswire Inc.Pharming Group announces the launch of an offering of approximately €100 million convertible bonds due 2029 and the concurrent repurchase of the outstanding €125 million convertible bonds due 2025EU:PHARMPharming Group NV
08/04/202407:00GlobeNewswire Inc.Pharming announces completion of enrollment in pediatric clinical trial of leniolisibEU:PHARMPharming Group NV
04/04/202408:30GlobeNewswire Inc.Pharming Group announces the 2024 Annual General Meeting of ShareholdersEU:PHARMPharming Group NV
04/04/202407:00GlobeNewswire Inc.Pharming Group announces the filing of its 2023 Annual Report and Form 20-FEU:PHARMPharming Group NV
03/04/202408:00GlobeNewswire Inc.Pharming Group to participate in April investor conferencesEU:PHARMPharming Group NV
14/03/202407:00GlobeNewswire Inc.Pharming Group reports fourth quarter and full year 2023 financial resultsEU:PHARMPharming Group NV
29/02/202408:00GlobeNewswire Inc.Pharming Group to report fourth quarter and full year 2023 financial results on March 14EU:PHARMPharming Group NV
08/02/202408:00GlobeNewswire Inc.Pharming Group to participate in February investor conferencesEU:PHARMPharming Group NV
08/01/202407:00GlobeNewswire Inc.Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch updateEU:PHARMPharming Group NV
13/12/202307:00GlobeNewswire Inc.Pharming Group announces development plans for leniolisib for additional primary immunodeficiencies (PIDs)EU:PHARMPharming Group NV
21/11/202307:00GlobeNewswire Inc.Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisibEU:PHARMPharming Group NV
10/11/202314:51GlobeNewswire Inc.Pharming Group provides updates on EMA regulatory review of leniolisib MAA and plans to file for UK regulatory approvalEU:PHARMPharming Group NV
01/11/202308:00GlobeNewswire Inc.Pharming Group to participate in November investor conferencesEU:PHARMPharming Group NV
26/10/202307:00GlobeNewswire Inc.Pharming Group reports third quarter 2023 financial resultsEU:PHARMPharming Group NV
12/10/202308:00GlobeNewswire Inc.Pharming Group to report third quarter 2023 financial results on October 26EU:PHARMPharming Group NV
25/09/202316:00GlobeNewswire Inc.Pharming Group reports on results of the 2023 Extraordinary General Meeting of ShareholdersEU:PHARMPharming Group NV
25/03/202300:22Dow Jones NewsADRs End Mostly Lower, Pharming Group Trades ActivelyEU:PHARMPharming Group NV
13/03/202309:34Dow Jones NewsPharming Expects to Have Access to $26 Million It Has on Deposit at SVB USEU:PHARMPharming Group NV
23/12/202111:02Dow Jones NewsPharming Group, Sanofi Renew Strategic Manufacturing Partnership AgreementEU:PHARMPharming Group NV
01/07/202107:00GlobeNewswire Inc.Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Thera...EU:PHARMPharming Group NV
09/08/201613:20Dow Jones NewsValeant Posts a Loss, Says It Will RetoolEU:PHARMPharming Group NV
06/03/201407:13GlobeNewswire Inc.Pharming Reports On Preliminary Financial Results 2013EU:PHARMPharming Group NV
24/02/201407:12GlobeNewswire Inc.PHARMING AND SALIX ANNOUNCE EXTENSION OF PDUFA ACTION DATE FOR RUCONEST(r)EU:PHARMPharming Group NV
08/11/201307:06GlobeNewswire Inc.PHARMING AND SANTARUS ANNOUNCE NEW DATA FROM OPEN-LABEL REPEAT TREATMENT STUDY WITH RUCONEST (RECOMBINANT HUMAN C1 ESTERASE I...EU:PHARMPharming Group NV
07/11/201307:10GlobeNewswire Inc.Pharming Reports On Financial Results For The First Nine Months Of 2013EU:PHARMPharming Group NV
09/10/201307:07GlobeNewswire Inc.Pharming announces EU12.0 million private equity placement with institutional investorsEU:PHARMPharming Group NV
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:EU:PHARM
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network